Items where authors include "Myers, K.N."
Up a levelArticle
Vanderlinden, A., Jones, C.G. orcid.org/0000-0003-2958-8322, Myers, K.N. et al. (2 more authors) (2023) DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells. British Journal of Cancer, 129. 1840. ISSN 0007-0920
Gagg, H. orcid.org/0000-0003-2763-0304, Williams, S.T., Conroy, S. et al. (9 more authors) (2023) Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research, 12. 954. ISSN 2046-1402
Carmell, N., Rominiyi, O. orcid.org/0000-0002-9724-0224, Myers, K.N. et al. (9 more authors) (2021) Identification and validation of ERK5 as a DNA damage modulating drug target in glioblastoma. Cancers, 13 (5). 944. ISSN 2072-6694
Bennett, L.G., Wilkie, A.M., Antonopoulou, E. et al. (8 more authors) (2020) MRNIP is a replication fork protection factor. Science Advances, 6 (28). eaba5974. ISSN 2375-2548
Barone, G., Arora, A., Ganesh, A. et al. (11 more authors) (2018) The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response. Oncotarget, 9 (50). pp. 29508-29524.
Myers, K.N., Barone, G., Ganesh, A. et al. (6 more authors) (2016) The bornavirus-derived human protein EBLN1 promotes efficient cell cycle transit, microtubule organisation and genome stability. Scientific Reports, 6. p. 35548. ISSN 2045-2322
Staples, C.J., Barone, G., Myers, K.N. et al. (10 more authors) (2016) MRNIP/C5orf45 Interacts with the MRN Complex and Contributes to the DNA Damage Response. Cell Reports, 16. pp. 1-11. ISSN 2211-1247
Barone, G., Staples, C.J., Ganesh, A. et al. (9 more authors) (2016) Human CDK18 promotes replication stress signaling and genome stability. Nucleic Acids Research. ISSN 0305-1048
Patil, A.A., Sayal, P., Depondt, M.L. et al. (9 more authors) (2014) FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents. Oncotarget, 5 (15). pp. 6414-6424. ISSN 1949-2553